Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma.

ABSTRACT: In patients with ocular hypertension or glaucoma, all treatments aim to lower intraocular pressure (IOP) by modulating aqueous humour (AH) production and/or uveoscleral and trabecular meshwork/Schlemm's canal AH drainage. PG analogues are considered to be the 'gold standard' treatment and are the most frequently used IOP-lowering agents. Recent data support an important role for NO in regulating IOP. Thus, novel PG analogues carrying a NO-donating moiety were recently advanced. Latanoprostene bunod (LBN) and NCX 470, NO-donating derivatives of latanoprost and bimatoprost, respectively, are examples of such compounds. LBN ophthalmic solution, 0.024% (Vyzulta™), showed greater IOP-lowering efficacy compared with that of Xalatan^® (latanoprost ophthalmic solution, 0.005%) or 0.5% ti

SUBMITTER: Impagnatiello F 

PROVIDER: S-EPMC6451067 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature